Allogeneic transplantation of selected CD34+ cells from peripheral blood: Experience of 62 cases using immunoadsorption or immunomagnetic technique

Bone Marrow Transplantation

Volumn 22, Issue 6, 1998, Pages 519-525

  Urbano Ispizua, A ^b   Solano, C ^b   Brunet, S ^b   De la Rubia, J ^b   Odriozola, J ^b   Zuazu, J ^b   Figuera, A ^b   Caballero, D ^b   Martinez C ^b   Garcia J ^b   Sanz, G ^b   Torrabadella, M ^b   Alegre, A ^b   Perez Oteiza J ^b   Jurado, M ^b   Oyonarte, S ^b   Sierra, J ^b   Garcia Conde J ^b   Rozman, C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NONE

Author keywords

Allogeneic transplantation; CD34+ selection; Peripheral blood progenitor cells

Indexed keywords

BUSULFAN; CD3 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CELL SEPARATION; CONDITIONING; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOADSORPTION; LEUKAPHERESIS; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; PRIORITY JOURNAL; SIBLING; T LYMPHOCYTE; THROMBOCYTE COUNT; WHOLE BODY RADIATION;

EID: 0031719315     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701386     Document Type: Article

References (48)

1. O'Reilly RJ. T cell depletion and allogeneic bone marrow transplantation. Semin Hematol 1992; 29 (Suppl. 1): 20-26.
2. +-selected peripheral blood progenitor cells mobilized by recombinant granulocyte- and granulocyte-macrophage colony-stimulating factors. Blood 1995; 86: 2052-2054 (letter).
3. + blood cells. Blood 1996: 87: 4903-4909.
4. + peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996; 88: 4132-4138.
5. + progenitor cells from matched related donors. Bone Marrow Transplant 1996; 18: 1081-1086.
6. + cells. Blood 1996; 88 (Suppl. 1): Abstr. 599a.
7. + selected cells from peripheral blood. Blood 1997; 89: 3967-3977.
8. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
9. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
10. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
11. Urbano-Ispizua A, Solano C, Brunet S et al. Allogeneic peripheral blood progenitor cells transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. Bone Marrow Transplant 1996; 18: 35-40.
12. Majolino I, Saglio G, Scime R et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17: 555-560.
13. Anderlini P, Przepiorka D, Khouri I et al. Chronic graft-vs-host disease (GVHD) after allogeneic marrow or blood stem cell transplantation. Blood 1995; 86 (Suppl. 1): Abstr. 108a.
14. Urbano-Ispizua A, García-Conde J, Brunet S et al. High incidence of chronic GVHD after allogeneic peripheral blood progenitor cell transplantation from matched related donors. Haematologica 1997; 82: 683-689.
15. Carbonell F, Calvo W, Fliedner TM et al. Cytogenetics studies in dogs after total body irradiation and allogeneic transfusion with cryopreserved blood mononuclear cells: observations in long-term chimeras. Int Cell Cloning 1984; 2: 81-88.
16. Civin CI, Trischmann T, Kadan NS et al. Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol 1996; 14: 2224-2233.
17. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
18. + cells from human bone marrow, cord blood, and mobilized peripheral blood. J Hematother 1993; 2: 333-338.
19. + cells of peripheral blood and marrow from related donors results in prompt engraftment and low incidence of GVHD in recipients undergoing allogeneic transplantation. Blood 1995; 86 (Suppl. 1): Abstr. 1543.
20. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832-843.
21. Kalbfleisch JD, Prentice RL (eds). Multivariate failure time data and competing risks. In: The Statistical Analysis of Fail- ure Time Data. John Wiley & Sons: New York, 1980, pp 170-173.
22. Schattenberg A, De Whitte T, Preijers F et al. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. Blood 1990; 75: 1356-1363.
23. Verdonck LF, de Gast GC, van Heugten HG, Deckker A. A fixed low number of T cells in HLA-identical allogeneic bone marrow transplantation. Blood 1990; 75: 776-780.
24. Verdonck LF, Dekker AW, de Gast GC et al. Allogeneic bone marrow transplantation with fixed low number of T cells in the marrow graft. Blood 1994; 83: 3090-3096.
25. Lowenberg B, Wagemaker G, van Bekkum DW et al. Graft-versus-host disease following transplantation of 'one log' versus 'two log' T lymphocyte-depleted bone marrow from HLA-identical donors. Bone Marrow Transplant 1986; 1: 133-140.
26. + stem cell augmentation of allogeneic, elutriated marrow grafts improves engraftment but cyclosporine A is still required to reduce GVHD and morbidity. Transplant Proc 1997; 29: 728-732.
27. Wagner JE, Santos GW, Noga SJ et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood 1990; 75: 1370-1377.
28. Aversa F, Tabilio A, Terenzi A et al. Successful engraftment of T-cell depleted haploidentical 'three loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
29. + cells from an HLA-identical unrelated donor. Bone Marrow Transplant 1995; 16: 719-722.
30. Waller CF, Bertz H, Wenger MK et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 1996; 18: 279-283.
31. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1995; 84: 1421-1426.
32. + selection of granulocyte colony-stimulating factor-mobilized allogeneic peripheral blood progenitor cells. Blood 1996; 88: 1517-1518 (letter).
33. Watts MJ, Sullivan AM, Ings SJ et al. Evaluation of clinical scale CD34 cell purification: experience of 71 immunoaffinity column procedures. Bone Marrow Transplant 1997; 20: 157-162.
34. + cells from fresh peripheral blood mononuclear cell preparations using two different separation techniques. J Hematother 1995; 4: 539-544.
35. + cells using the Amgen cell selection device results in high levels of purity and recovery. J Hematother 1997; 6: 5-11.
36. + selection systems or CAMPATH-1. Exp Hematol 1995; 23: 147-154.
37. +TM stem cell releasing agent. In: Latest advancements in immunomagnetic cell selection for grafts engineering in autologous and allogeneic stem cell transplantation. EBMT Baxter satellite syposium. Vienna, 3 March 1996.
38. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
39. Noga SJ, Davis J, Schepers K et al. The clinical use of elutriation and positive stem cell selection columns to engineer the lymphocyte and stem cell composition of the allograft. Prog Clin Biol Res 1994; 389: 317-324.
40. + cell dose predicts survival, postransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-3229.
41. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
42. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
43. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
44. Marmont A, Horowitz MM, Gale RP et al. T-cell depletion of HLA - identical transplants in leukemia. Blood 1991; 78: 7120-2130.
45. Kernan NA. T-cell depletion for prevention of graft-versus-host disease. In: Forman SJ, Blume KG. Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publishers: Boston, 1994, pp 124-135.
46. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T-cell depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986; 68: 770-773.
47. Bensinger WI, Rowley S, Lilleby K et al. Reduction in graft versus host disease (GVHD) after transplantation of CD34 selected allogeneic peripheral blood stem cells (PBSC) in older patients with advanced hematologic malignancies. Blood 1996; 88 (Suppl. 1): Abstr. 421a.
48. Gale RP, Bortin MM, Van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.